The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents
作者:Michael P. DeNinno、Melissa Andrews、Andrew S. Bell、Yue Chen、Cynthia Eller-Zarbo、Nan Eshelby、John B. Etienne、Dianna E. Moore、Michael J. Palmer、Michael S. Visser、Li J. Yu、William J. Zavadoski、E. Michael Gibbs
DOI:10.1016/j.bmcl.2009.03.024
日期:2009.5
lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.
从非选择性吡唑并嘧啶酮开始,并行使用药物化学和定向合成技术导致发现了有效的,高度选择性的,可口服生物利用的PDE9抑制剂。这些工具的可用性允许对PDE9抑制作用的治疗潜力进行全面评估。